Cancer Discov. 2023 Dec 12;13(12):2492. doi: 10.1158/2159-8290.CD-NB2023-0079.
In a phase I trial of the MTA-cooperative PRMT5 inhibitor AMG 193, five of 39 patients with advanced MTAP-deleted solid tumors who had scans following initial treatment experienced partial responses. The responses occurred in five tumor types-esophageal, pancreatic, renal cell, gallbladder, and ovarian Sertoli-Leydig cell cancer.
在MTA合作的PRMT5抑制剂AMG 193的I期试验中，39例患有晚期MTAP缺失实体瘤的患者在初始治疗后进行扫描，其中5例出现部分缓解。这些缓解出现在五种肿瘤类型中，即食管癌、胰腺癌、肾细胞癌、胆囊癌和卵巢支持-间质细胞瘤。
